24 Jul 2026 Part 2 of 2No, they are not Optimus Jr, Megatron’s clones, or any other new, amyloid-shattering members of the Tron family franchise of transformer robots, though perhaps Roche does not mind if you think so for a moment. Rather, the TRONTIER twins are currently enrolling Phase 3 trials for early AD, and […]
Across three independent studies, the NeuLogiq® Platform two-minute tablet-based Symbol Swap task delivered clinically meaningful discrimination between control, MCI and Alzheimer’s dementia groups and detected blood-biomarker-defined pathology — including in clinically normal individuals — with accuracy matching or exceeding the ADAS-Cog, MoCA and MMSE benchmarks. LONDON, July 15, 2026 /PRNewswire/ — Cumulus Neuroscience (Cumulus; The Company), a global […]
Symbol Swap matched or exceeded ADAS-Cog, MoCA, and MMSE across three independent studiesBy Henry BakerPublished: Jul 15 2026, 3:39 PM EDT On the final day of the world’s largest dementia research conference, a startup presented data Wednesday suggesting that a two-minute tablet task can do what a trained clinician typically takes 10 to 45 minutes to […]
GAP Experts Share Poster Presentations at Alzheimer’s Association International Conference (AAIC) Washington D.C., July 9, 2026- The Global Alzheimer’s Platform Foundation®, (GAP) will have two poster presentations at the 2026 Alzheimer’s Association International Conference (AAIC) being held in Londong July 12 through July 15. All posters are in the Exhibit Hall in Excel London, Royal Victoria Dock, 1 […]
By:Ingrid Johansen, Date: July 7, 2026 A significant global research initiative is underway to develop a convenient blood test for diagnosing Alzheimer’s disease. The study focuses on three specific proteins linked to the condition, aiming to compare the efficacy of the test with current brain scans. If successful, this new test could offer a simpler […]
Washington D.C., July 1, 2026- Elevance Health, formerly Anthem Inc., updated their medical policy, to allow for blood-based biomarker testing for the detection and diagnosis of Alzheimer’s disease, making Elevance Health one of the first major payors to outline coverage criteria. GAP President John Dwyer said, “GAP applauds the decision by Elevance Health to explicitly endorse […]
John Dwyer, the President of the Global Alzheimer’s Platform Foundation (GAP) joins TrialSiteNews to discuss a collaboration and partnership with Circular Genomics. The partnership will analyze blood test samples to investigate the potential for circular RNA biomarkers to assist in the diagnosis & treatment of Alzheimer’s Disease. Topics covered: Press Release: https://globalalzplatform.org/2026/05…
Story by Amy Scherzer, Bay Correspondent Tearful yet joyful, the annual Inspire, Imagine & Hope Gala honored Tampa neurologist Dr. Susan Steen for her 40-plus years advancing brain health education and leading clinical trials for Alzheimer’s disease, Parkinson’s disease and multiple sclerosis. Gala co-chairs Lyle Fogarty and Dr. Shannon Moroney shared the personal impact of […]
Collaboration to accelerate the investigation of Alzheimer’s disease biomarkers with early access to Bio-Hermes-001 data Washington D.C., May 28, 2026 – The Global Alzheimer’s Platform Foundation® (GAP) is pleased to announce a collaboration with the Circular Genomics, a biotechnology company revolutionizing neurological and psychiatric precision medicine, access to analyze Bio-Hermes-001 samples to investigate the potential for circular RNA […]
TrialSite Staff | Making Biomedical Research Evidence Accessible to All May. 18, 2026, 2:30 p.m. The global battle against Alzheimer’s disease may increasingly hinge on one critical factor: detecting the disease earlier, faster, and more accurately before irreversible neurological decline takes hold. This week, the Global Alzheimer’s Platform Foundation (GAP) announced the continued expansion of its Bio-Hermes-002 […]
The Global Alzheimer’s Platform Foundation expands the Bio-Hermes-002 study, incorporating Sanofi and other industry leaders, to refine blood and digital biomarkers for more inclusive, earlier diagnosis of dementia… The Global Alzheimer’s Platform Foundation expands the Bio-Hermes-002 study, incorporating Sanofi and other industry leaders, to refine blood and digital biomarkers for more inclusive, earlier diagnosis of […]
Bio-Hermes-002 is a collaborative study focused on new biomarkers designed to improve diagnosis of Alzheimer’s disease and dementias. Washington D.C., May 18, 2026 – The Global Alzheimer’s Platform Foundation® (GAP) is pleased to announce the continued expansion of the Bio-Hermes-002 study, a unique observational platform study, which evaluates blood-based and digital biomarkers across a wide spectrum of cognitive conditions, alongside MRI and PET imaging and diverse […]
Could Alzheimer’s disease one day be detected with a simple blood test instead of expensive brain scans? In this episode of the TrialSite News Farago Podcast, we speak with John Dwyer, President and CEO of the Global Alzheimer’s Platform Foundation (GAP), about the Bio-Hermes-002 study and the future of Alzheimer’s detection. The conversation explores how […]
Representatives from Butler Hospital’s Memory and Aging Program and the Global Alzheimer’s Platform recently visited the Swansea Council on Aging to discuss normal memory changes with age and new research in Alzheimer’s prevention. The session also encouraged residents to engage with the Acti-v8 initiative and join a prevention registry. This content is adapted from materials provided by Swansea Council On Aging This article includes […]
Houston, Texas (April 15, 2026) – Re:Cognition Health, a global leader in new treatments for Alzheimer’s Disease, is delivering an international clinical trial to evaluate whether a simple finger-prick blood test can revolutionize how Alzheimer’s disease is diagnosed. Compared with the current invasive and expensive diagnostic methods, this approach could provide a scalable solution for […]
Apr 17, 2026 | Dementias & Alzheimer’s, Immunoassay | The study will analyze three key proteins to determine if blood-based biomarkers can provide an earlier and more accessible diagnostic method. Re:Cognition Health is delivering an international clinical trial to evaluate whether a finger-prick blood test can improve how Alzheimer’s disease is diagnosed. Compared with current invasive and expensive diagnostic methods, this approach aims […]
Siemens Healthineers has become a licensed partner in the Bio-Hermes-002 Alzheimer’s study. Erin Brady April 13, 2026 The Global Alzheimer’s Platform Foundation (GAP) has announced that Siemens Healthineers has joined the Bio-Hermes-002 study alongside several other industry leaders. Siemens is now a licensed partner of the study, aiming to enhance Alzheimer’s diagnostics. Specifically, Siemens Healthineers will work to “change the paradigm […]
The Global Alzheimer’s Platform Foundation (GAP) has announced a strategic collaboration with Siemens Healthineers for the Bio-Hermes-002 study, an observational platform designed to evaluate biomarkers for Alzheimer’s disease and related dementias. The study compares blood-based and digital biomarkers across a wide range of cognitive conditions, alongside MRI and PET imaging data, to generate insights that […]
Siemens Healthineers joins collaborative study focused on new biomarkers designed to improvediagnosis of Alzheimer’s disease and dementias Washington D.C., Apr. 9, 2026 – The Global Alzheimer’s Platform Foundation® (GAP) is pleased to welcome Siemens Healthineers, a leading global medical technology provider pioneering breakthroughs in healthcare, to the Bio-Hermes-002 study. This collaboration will enhance this unique, […]
Colleagues, Trusted Partners, & Friends, We want to share a brief update on how Q1 of 2026 unfolded for the Global Alzheimer’s Platform Foundation (GAP) and the significant work anticipated ahead. In January, our work received global coverage as the British Broadcasting Corporation (BBC) spotlighted the Bio-Hermes-002 (BH2) study in a story about a finger prick blood test […]
Tampa, FL, Mar 25, 2026— Axiom Brain Health (Axiom) is pleased to announce Dr. Susan Steen will be honored by the Alzheimer’s Association – Florida Gulf Coast Chapter at the Inspire, Imagine, and Hope Gala on Friday, March 27, 2026, at The Gathering @ Armature Works in Tampa. “I am delighted to receive this honor from the […]
By Knowridge -March 25, 2026Alzheimer’s disease is one of the most common causes of memory loss in older adults. It slowly affects the brain, making it harder for people to remember things, think clearly, and carry out daily activities. As the global population ages, more and more families are facing the challenges of this condition. Because of […]
The Global Alzheimer’s Platform Foundation’s® (GAP) 2025 Citizen Scientist Award® recipients announced in Las Vegas WASHINGTON, DC (Feb. 27, 2026) — Today, the Global Alzheimer’s Platform Foundation (GAP) proudly announced the 2025 National Citizen Scientist Awards® elevated honorees. GAP’s Citizen Scientist Awards (CSA) acknowledge the contributions of individuals who make a difference by volunteering in clinical trials for neurodegenerative diseases. This year’s award […]
Long before Alzheimer’s disease became a global crisis, it was already shaping quiet, devastating stories inside individual families. Science was fragmented. Treatments were elusive. And for decades, progress moved more slowly than anyone anticipated. For entrepreneurs working in healthcare, the challenge was not just scientific. It was structural. How do you build companies that can […]